Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User

Description

List of Tables

[192 Pages Report] The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 4.14 billion in 2023 and expected to reach USD 4.57 billion in 2024, at a CAGR 11.13% to reach USD 8.68 billion by 2030.

Global Next-Generation Breast Cancer Diagnostic & Screening Market

KEY MARKET STATISTICS
Base Year [2023]	USD 4.14 billion
Estimated Year [2024]	USD 4.57 billion
Forecast Year [2030]	USD 8.68 billion
CAGR (%)	11.13%

Next-Generation Breast Cancer Diagnostic & Screening Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Accessories
- Breast Imaging Systems
- Software & Services
Diagnostic Technology
- DNA Microarrays
- Lab-on-a-Chip & Reverse Transcriptase-PCR
- Molecular Diagnostics
- Next Generation Sequencing
- Protein Microarrays
- qPCR & Multiplexing
Screening Technology
- Ionizing Breast Imaging Technologies
  - 3D Breast Tomosynthesis
  - Analog Mammography
  - Cone-Beam Computed Tomography (CBCT)
  - Contrast-Enhanced Mammography (CEM)
  - Full-Field Digital Mammography (FFDM)
  - Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
  - Positron Emission Mammography (PEM)
  - Positron Emission Tomography and Computed Tomography (PET-CT)
- Non-ionizing Breast Imaging Technologies
  - Automated Whole-Breast Ultrasound (AWBU)
  - Breast MRI
  - Breast Thermography
  - Breast Ultrasound
  - Electric Impedance Tomography
  - Optical Imaging
Application
- Cancer Screening
- Companion Diagnostics
- Risk Analysis
- Therapeutic Monitoring
End User
- Breast Care Centers
- Diagnostic Imaging Centers
- Hospitals & Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Breast Cancer Diagnostic & Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Breast Cancer Diagnostic & Screening Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Breast Cancer Diagnostic & Screening Market?

4. What is the market share of the leading vendors in the Next-Generation Breast Cancer Diagnostic & Screening Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Breast Cancer Diagnostic & Screening Market?

Product Code: MRR-5C6F41F5B007

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Next-Generation Breast Cancer Diagnostic & Screening Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of breast cancer worldwide
  - 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
  - 5.1.1.3. Government initiatives to raise awareness regarding breast cancer
- 5.1.2. Restraints
  - 5.1.2.1. High cost of manufacturing of breast cancer diagnostic & screening technologies
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
  - 5.1.3.2. Strategic alliances and investments to manufacture innovative bread cancer diagnostic solutions
- 5.1.4. Challenges
  - 5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product

6.1. Introduction
6.2. Accessories
6.3. Breast Imaging Systems
6.4. Software & Services

7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology

7.1. Introduction
7.2. DNA Microarrays
7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
7.4. Molecular Diagnostics
7.5. Next Generation Sequencing
7.6. Protein Microarrays
7.7. qPCR & Multiplexing

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology

8.1. Introduction
8.2. Ionizing Breast Imaging Technologies
- 8.3.1. 3D Breast Tomosynthesis
- 8.3.2. Analog Mammography
- 8.3.3. Cone-Beam Computed Tomography (CBCT)
- 8.3.4. Contrast-Enhanced Mammography (CEM)
- 8.3.5. Full-Field Digital Mammography (FFDM)
- 8.3.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
- 8.3.7. Positron Emission Mammography (PEM)
- 8.3.8. Positron Emission Tomography and Computed Tomography (PET-CT)
8.3. Non-ionizing Breast Imaging Technologies
- 8.4.1. Automated Whole-Breast Ultrasound (AWBU)
- 8.4.2. Breast MRI
- 8.4.3. Breast Thermography
- 8.4.4. Breast Ultrasound
- 8.4.5. Electric Impedance Tomography
- 8.4.6. Optical Imaging

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

9.1. Introduction
9.2. Cancer Screening
9.3. Companion Diagnostics
9.4. Risk Analysis
9.5. Therapeutic Monitoring

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

10.1. Introduction
10.2. Breast Care Centers
10.3. Diagnostic Imaging Centers
10.4. Hospitals & Clinics

11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories
- 15.1.2. Agendia Inc.
- 15.1.3. Agilent Technologies, Inc.
- 15.1.4. ARTIVION INC.
- 15.1.5. Becton, Dickinson and Company
- 15.1.6. Benitec Biopharma Ltd
- 15.1.7. BGI Genomics Co., Ltd.
- 15.1.8. Bio-Rad Laboratories, Inc.
- 15.1.9. Centogene N.V.
- 15.1.10. Danaher Corporation
- 15.1.11. Epic Sciences, Inc.
- 15.1.12. Exact Sciences Corporation
- 15.1.13. F. Hoffmann-La Roche Ltd.
- 15.1.14. Fujifilm Holdings Corporation
- 15.1.15. GE HealthCare Technologies, Inc.
- 15.1.16. Hologic, Inc.
- 15.1.17. Illumina, Inc.
- 15.1.18. Invivoscribe, Inc.
- 15.1.19. Koninklijke Philips N.V.
- 15.1.20. Laboratory Corporation of America Holdings
- 15.1.21. Merck & Co., Inc.
- 15.1.22. Myriad Genetics, Inc.
- 15.1.23. Novartis AG
- 15.1.24. Pfizer Inc.
- 15.1.25. QIAGEN N.V.
- 15.1.26. Siemens Healthineers AG
- 15.1.27. Thermo Fisher Scientific Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing